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ABSTRACT
Poor prognosis and high recurrence remain leading causes of primary liver 
cancer–associated mortality. The spread of circulating tumor cells (CTCs) in the 
blood plays a major role in the initiation of metastasis and tumor recurrence after 
surgery. Nevertheless, only a subset of CTCs can survive, migrate to distant sites and 
establish secondary tumors. Consistent with cancer stem cell (CSC) hypothesis, stem-
like CTCs might represent a potential source for cancer relapse and distant metastasis. 
Thus, identification of stem-like metastasis-initiating CTC-subset may provide useful 
clinically prognostic information. This review will emphasize the most relevant findings 
of CTCs in the context of stem-like biology associated to liver carcinogenesis. In this 
view, the emerging field of stem-like CTCs may deliver substantial contribution in 
liver cancer field in order to move to personalized approaches for diagnosis, prognosis 
and therapy.
STEMNESS  ASPECTS  OF  PRIMARY 
LIVER  CANCER  
Primary liver cancer (PLC) is one of the most 
common cancers worldwide and second leading cause 
of cancer-related mortality [1, 2]. Primary liver tumors 
are grossly classified in hepatocellular carcinoma (HCC) 
and cholangiocarcinoma (CCA) [1, 3-5]. HCC accounts 
for approximately 90% of all PLC [1, 3], while CCA, 
a rare tumor but with an increasing global incidence, is 
the second most common form and accounts for about 
5% of all PLC [3-5]. Although liver transplantation, 
surgical resection and locoregional therapies are effective 
therapeutic options at early phases, the majority of PLC 
patients still present unresectable stages of the disease, 
for which curative options are limited [2]. Currently, the 
standard-of-care treatment for advanced liver cancer is 
limited to systemic chemotherapy [1, 5-9]. Unfortunately, 
results of ongoing clinical trials are discouraging overall 
and they highlight the urgent need for innovative 
treatment approaches [10-17]. Additionally, traditional 
clinicopathological parameters such as tumor morphology, 
histopathological features and tumor staging system 
offer limited information for predicting postoperative 
recurrence [1, 5]. Thus moving to prognostic models for a 
personalized approach is essential.
The phenotypic overlap between HCC and CCA 
has been shown to comprise a continuous liver cancer 
spectrum [18-20]. In this respect, new exciting insights 
into tumor biology have been recently provided since the 
discovery of cancer stem cells (CSCs) in many human 
solid tumors including liver cancer [2, 21-29]. CSCs 
represent a cellular subset within a tumor endowed with 
stem-like properties such as the ability for self-renewal 
and differentiation as well as the resistance to drugs [29, 
30]. More importantly, CSCs are thought to be responsible 
for tumor initiation, recurrence and metastasis showing 
reduced sensitivity to chemotherapy compared to bulk 
tumor cells [21, 22, 29, 31]. Indeed growing evidence 
confirmed that PLC-CSCs are characterized by higher 
resistance to commonly used therapeutic drugs (e.g. 
cisplatin, 5-fluorouracil and Sorafenib) [32-39]. 
It is now becoming accepted that CSCs represent a 
dynamic and very plastic population [40]. Truly, strength 
of their plasticity has been certainly given by the aberrant 
activation of a latent embryonic program (known as the 
epithelial-mesenchymal transition, EMT) that can generate 
undifferentiated cancer cells endow with stemness traits 
[30, 41, 42]. Therefore, EMT-process provides a ready 
source of CSC-state by enabling the dedifferentiation of 
epithelial cells within tumor bulk [30, 41, 43-45]. Since 
CSCs are defined as dynamic entities, accumulating 
evidence has revealed that tumor microenvironment, 
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defined by signals and cellular interactions arising in 
the CSC-associated niche [22, 46-48], is involved in 
regulation and maintenance of stem-like features. Notably, 
stroma-component of CSC-niche may secrete signaling 
factors involved in the activation of EMT-programs.
During the last decade there has been a great 
quantity of studies aimed to identify liver CSCs and 
several attempts have been made to enrich CSCs in hepatic 
tumors. Common strategies for PLC-CSC enrichment, 
varied from the widely used classical antigenic approaches 
based on the identification of surface stem-like markers 
(e.g. CD133 [31, 49, 50], CD44 [51], OV6 [52], CD90 
[53, 54], epithelial cell adhesion molecule (EpCAM) [55, 
56], CD13 [57], CD24 [58], CD47 [59]) to functional 
methodologies including Side Population analysis [23, 60], 
Aldefluor assay [61] and sphere formation coupled with 
serial sphere passaging [62, 63]. In all diverse published 
studies, enriched PLC stem-like subsets were tested 
in immune-deficient mice for the in vivo tumorigenic 
potential [23, 31, 49-63] (Table1). More interestingly 
only those putative PLC stem-like subpopulation capable 
to initiate tumor development at low cell numbers, were 
further tested for ‘self-renewal’ capacity in serial tumor 
transplantations and molecularly for presence of hepatic 
stemness-related pathways (e.g. developmental signaling 
and transcription factors, epigenetic regulation including 
specific miRNAs) [23, 62, 64-94] (Table2 and reviewed 
in [47]). Although a clear phenotypic and functional 
heterogeneity among the identified liver stem-like cancer 
subsets [2, 47], PLC-CSCs’ enrichment by different 
approaches suggests a possible overlapping within several 
tumorigenic populations. Hence, a combinatorial strategy 
might be a valid alternative to isolate a better-defined 
stem-like subset.
Furthermore, complexity of PLC-CSC heterogeneity 
can be deciphered in the context of stem-like plasticity [2, 
47, 95]. Indeed during normal stem cell development, a 
continuum of stem/progenitor states implied a high degree 
of stemness variety [2, 42].
In this view, a better knowledge of liver CSC-
biology and its role in human PLC-dissemination is 
essential to develop new molecular therapies effective in 
prolonging long-term survival in liver cancer patients [2, 
47].
METASTATIC CASCADE: EPITHELIAL-
MESENCHYMAL PLASTICITY AND 
CIRCULATING TUMOR CELLS
Tumor metastasis represents a multistep process 
by which neoplastic cells escape the physical barriers 
at the primary site, enter the circulation, disseminate 
and proliferate into secondary sites [96, 97]. As a part 
of metastatic cascade, tumor cells lose their cell-to-cell 
adhesion and undergo EMT in order to enter bloodstream. 
Subsequently, the exit from circulation and generation 
of micrometastasis are both driven by the EMT-reverse 
program, the mesenchymal-epithelial transition (MET) 
[97-99]. Thus epithelial-mesenchymal plasticity is critical 
hallmark during the disseminating evolution suggesting 
that EMT drives tumor cell circulation while successive 
MET the metastatic colonization [96, 100, 101]. 
As tumor dissemination mainly occurs through the 
blood, the circulating tumor cells (CTCs) branch from 
tumor mass into the vasculature on their way to metastatic 
sites [99, 101-105]. The spread of CTCs released in the 
bloodstream from primary or metastatic tumors represents 
the major responsible for metastasis initiation and tumor 
recurrence [102, 106]. This highlights the reason why 
CTCs have recently emerged as potential novel biomarkers 
in oncological field.
According to several experimental and clinical 
studies, only a minim percentage of CTCs can survive in 
the bloodstream and within them a small subset is able to 
form macrometastasis in a diverse organ [96, 101, 103]. 
Therefore, metastatic-colonization is rather inefficient and 
not all primary tumor cells possess metastatic potential. 
Indeed, once in the bloodstream, CTCs meet three main 
obstacles to their survival and dissemination: 1) shear 
forces and collisions with leukocytes generated by blood 
flow, 2) defense activity of immune system, 3) absence of 
cell-matrix interactions that triggers an apoptotic process 
called anoikis. When CTCs overcome these impediments, 
they migrate into target tissue throw the association with 
platelets and endothelial cells lining the vessels [103]. 
However, during this step they can be entrapped in small 
capillaries, leading to the arrest of the disseminating 
process [96]. At the end, instead of total CTCs, less than 
0,01% of CTCs are able to complete the late events of 
metastasis, representing the real initiating source of 
metastatic process [96, 99, 101, 103].
Several evidences suggest that distant organs are 
not casual target of metastatic process. Definitely, released 
signals from primary tumors (e.g. cytokines, exosomes, 
enzymes, etc.) are able to influence the microenvironment 
of target tissues, leading to the generation of a permissive 
pre-metastatic niche before CTC-extravasation [103]. 
Moreover, metastatic microenvironment may promote 
and support cancer cell dormancy, a state in which 
disseminated metastasis-initiating cells remain occult 
for an unlimited period of time [96, 99]. For this reason, 
patients may potentially remain in a clinical latency for 
years before appropriate microenvironmental signals re-
activate proliferation of dormant tumor cells (DTCs) [96, 
103]. Notably, cellular dormancy infers a quiescent non-
proliferative state of tumor cells rendering them resistant 
to conventional therapies. Thus, targeting DTC-viability 
related-mechanisms might lead to eradication of residual 
disease and metastatic prevention [99, 103, 107]. 
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Table 1: Isolation of Liver CSCs
Methods Frequency (%) Minimal Cell Number for Tumor Initiation References
Cell Surface Markers
CD133 0-65 1000 [31, 49, 50] 
CD44 0.1-1.9 100 [51]
OV6 0.2-3 5000 [52]
CD90 0-2.5 500 [53, 54]
EpCAM 0-99 200 [55, 56]
CD13 0.5-1.6 500 [57]
CD24 0.5-97 500 [58]
CD47 9.3-81 500 [59]
Functional Assays
Side Population 0.25-1.2 100 [23, 60]
Aldefluor 1-55 500 [61]
Sphere Culture 1-60 100 [62, 63]
Summary of different methods used to isolate liver CSCs. Frequency of isolated CSCs and their minimal cell 
number required for tumor initiation are indicated for each assay or marker used, with the respective references.
Table 2: Stemness-Related Signalings in Liver CSCs
Developmental Pathways and Transcription Factors References
Wnt Embryonic development, cell fate determination, cell proliferation [64-67]
Notch Cell-fate decision during embryonic development and adult life, regulator of self-renewing tissues [68-73]
Hedgehog Key regulator of embryonic development [74-76]
TGF-β Stem cell renewal and lineage specification; however has a controversial role on HCC genesis as a results from its effect on tumor microenvironment [77-81]
Bmi1 Stem cell factor, proto-oncogene [64, 82, 83]
Sall4 Key factors for maintenance of pluripotency and self renewal of embryonic stem cell potentially through the interaction with Oct4,Sox2, Nanog [84-86]
Epigenetic Regulators References
HDAC3 Histone acetylation/deacetylation alters chromosome structure, affects transcription factor access to DNA thus impacts cell cycle progression and developmental events [87, 88]
DNMT1
DNMT3b
DNA methylation patterns are essential for embryonic stem cell maintenance, mammalian 
development and normal functioning of adult organism [23, 62, 88, 89]
miRNAs References
miR-142-3p
miR-130b Regulation of self-renewal capability of CD133+ cells [90, 91]
miR-Let7 Inhibited by Lin28, marker of human embryonic stem cells [92, 93]
miR-181 Regulation of Wnt/β-catenin pathway [94]
Summary of stemness-related signalings with a role in liver CSC biology. Functions and relative references are indicated for 
each pathway, transcription factor, epigenetic regulator or miRNA.
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CTCs AND LIVER CANCER
High recurrence rate, most likely due to undetectable 
micrometastasis present at initial stage [108] is one of the 
principal causes of liver cancer death [109]. Investigation 
of PLC-CTCs is still at their very beginning in comparison 
with other tumor systems, particularly breast cancer. 
However recent evidence has revealed the importance of 
CTCs in liver carcinogenesis. Although CTCs represent 
a very challenging subset to be detected in peripheral 
blood (~1 CTC for every 107 blood cells), analysis of 
circulating liver cancer cells is of fundamental relevance 
to provide safer, less painful, more accessible and dynamic 
information for recurrence and survival prediction [102, 
106, 110, 111], thus highlighting its potential utility in 
PLC-surveillance. Instead of classical in situ biopsies 
and radiologic techniques, repeated collection of PLC-
CTCs could be indeed used to monitor response to 
therapy [112-115], as already described in other solid 
tumors (e.g. melanoma [116], pancreatic [117], prostate 
[118, 119] breast [120-122], lung [123, 124] gastric 
[125] and colorectal cancer [126, 127]). Therefore CTC-
analysis may be considered as ‘liquid biopsy’ with the 
theoretical advantage of serial sample collection and 
real time monitoring of disease progression [101, 108, 
112, 128-130]. Indeed, molecular information derived 
from liquid biopsy could be potentially useful for a better 
understanding of molecular alterations that control tumor 
development and progression [129, 130].
Current methods for CTC-isolation and detection 
are described in BOX1 and summarized in Figure 1. In 
liver cancer, most evaluating CTC-studies widely employ 
immunoaffinity EpCAM-based methods [106, 108, 109, 
131-133]. PLC-CTC number is very broad within a certain 
study and between the different studies reported below 
[53, 54, 108, 109, 112, 113, 115, 128, 131-138], likely due 
to the sample heterogeneity and technical platforms used 
for CTC-isolation.
Evidence of CTCs in hepatocarcinoma
Although the hematogenous spread of CTCs from 
primary HCC is a crucial step in metastatic cascade, 
Figure 1: Different Approaches for CTC-Enrichment. There are different conventional approaches for CTC-enrichment, based on 
diverse biological features. A first group is based on physical properties of CTCs, such as size, density and electric charge. The second group 
is based on immunoaffinity. In this case positive-selective techniques use microbeads targeting CTC-specific antigen, whereas microbeads 
targeting red or white blood cells are used in negative-selective strategies. The third group is represented by microfluidic-based platforms 
that incorporate a combination of size- and immunoaffinity-based approaches, thus representing a combination of the previous two groups.
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Table 3: Summary of CTC studies in PLC patients
N° of 
Patients Platform
Method for 
Detection
CTC 
Phenotype
CTC 
Number/
Frequency
Method for 
Characterization Correlation/Outcome References
HCC patients
36 PLC na
Ficoll gradient  + 
CD45 depletion 
and CD90 magnetic 
selection
CD45- CD90+ 
CD44+ 0-6.9 %
In vivo tumorigenic 
assay, qRT-PCR Tumor size [53]
34 PLC na Flow cytometry  CD45- CD90+ 0-1.2 % In vivo tumorigenic assay na [54]
59 CellSearch System Positive immuno-magnetic selection  
DAPI+ CD45- CK+ 
EpCAM+  
0-5 / 
7.5mL na 
OS, BCLC stage, 
vascular invasion, AFP 
level 
[108]
123
87 CellSearch System Positive immuno-magnetic selection 
DAPI+ CD45- CK+ 
EpCAM+ 
1-34 / 
7.5mL Immunofluorescence
Recurrence, TTR, 
AFP level, vascular 
invasion, Edmondson 
stage
[109]30
RosetteSep 
Human CD45 
Depletion Cocktail 
 Negative immuno-
magnetic selection  CD45-
1-34 / 
7.5mL qRT-PCR assays 
Recurrence, TTR, 
AFP level, vascular 
invasion, Edmondson 
stage
6  na Magnetic-activated cell sorting CD45- EpCAM+ 
1-34 / 
7.5mL
 In vivo tumorigenic 
assay
Recurrence, TTR, 
AFP level, vascular 
invasion, Edmondson 
stage
21
1 CellSearch System Positive immuno-magnetic selection 
DAPI+ CD45- CK+ 
EpCAM+ 
0.14 ± 0.65 
/ 7.5mL na na 
[106]
19 IsoFlux
Ficoll gradient 
+ EpCAM-
based magnetic 
selection on 
microfluidic device
Hoecht 33342+ 
CD45- 
CK+ EpCAM+ 
127.52 ± 
295.15 / 
7.5mL 
Immunofluorescence na
20 CellSearch System
Positive immuno-
magnetic selection  
DAPI+ CD45- CK+ 
EpCAM+  
0-79 / 
7.5mL Genome sequencing 
AFP level, vascular 
invasion [131]
85 AutoMACS Pro Separator
Ficoll gradient + 
ASGPR-based 
magnetic selection  
DAPI+ CD45- 
ASGPR+ HepPar1+ 
19 ± 24 / 
5mL 
Immunofluorescence, 
FISH, qRT-PCR
Portal vein thrombus, 
Milan criteria, 
Edmondson/TNM 
stage, tumor size
[128]
109 na Negative immuno-magnetic selection 
DAPI+ CD45- CK+ 
pERK/Akt+ 
52 ± 23 / 
5mL Immunofluorescence 
PFS, therapeutic 
response to Sorafenib [113]
299
 RosetteSep 
Human CD45 
Depletion 
Cocktail
 Negative immuno-
magnetic selection CD45- EpCAM+
41.2-
54.5% 
qRT-PCR for 
EpCAM 
Treatment response, 
TTR, recurrence [115]
60 MiniMACS Separator
Ficoll gradient + 
ASGPR-based 
magnetic selection  
HSA+ DAPI+ 
CD45- ASGPR+ na Immunofluorescence
Recurrence, portal 
vein thrombus, Milan 
criteria, Edmondson/
TNM stage, tumor size
[135]
11
 RosetteSep 
Human CD45 
Depletion 
Cocktail
 Negative immuno-
magnetic selection
DAPI+ CD45- 
panCK/EpCAM/
ASGPR1+ 
Ncadherin/
vimentin+
5-275 CK+ 
/ 1000 
PBMC
Immunofluorescence TTP, cirrhosis [146]
82 na Ficoll gradient CD45- CD90+ CD44+ 0-0.02% Flow cytometry
Tumor size, TNM 
stage, recurrence [149]
96 na Ficoll gradient Lin28B+ na qRT-PCR for Lin28B
Recurrence, tumor 
grade, tumor size, 
AJCC/BCLC stage, 
[154]
2 na Flow cytometry CD45- ICAM1+ 0.3 ± 0.02 %
Sphere assay, 
in vivo tumorigenic 
assay
OS, portal vein 
thrombus, ascites [155]
44 ISET Cell size β-catenin mutated na Nested PCR for β-catenin 
Tumor diffusion, portal 
tumor thrombosis, 
survival, Child-Pugh 
class, AFP level
[172]
CCA patients
36 PLC na
Ficoll gradient  + 
CD45 depletion 
and CD90 magnetic 
selection
CD45- CD90+ 
CD44+ 0-6.9 % qRT-PCR Tumor size [53]
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correlation of HCC progression and treatment-response to 
CTC-numbers remains to be elucidated.
Xu et al. measured CTCs in blood samples from 
85 HCC patients at various stages and defined them as 
cell with larger cell size, intact nuclei, high nucleus-to-
cytoplasm ratio, CD45- (leukocytes marker) and HepPar1+ 
(a hepatocyte-specific marker, which binds mitochondria 
antigens present in liver-derived cells). The authors 
showed that CTCs could be detected in 81% of HCC 
patients, even at early stage or with tumor size lesser than 
2 cm, with a CTC-number ranged from 0 to 125 per 5 mL 
of blood, whereas no CTCs were identified in any of the 
healthy subjects’ blood samples. These data confirmed that 
tumor blood-borne dissemination could represent a very 
early event. Moreover, the positivity rate and the number 
of CTCs statistically correlated with portal vein tumor 
thrombus, tumor size, grading (defined by Edmondson-
Steiner grading) and tumor-node-metastasis (TNM) 
staging. Interestingly, the positivity rate and number of 
CTCs was statistically higher in patients who did not 
meet the Milan criteria (commonly used to select patients 
eligible for liver transplantation) suggesting that CTC-
amount could be better indicator of liver transplantation 
eligibility, thus directing the most suitable therapeutic 
intervention. Importantly, in order to minimize false-
positive results during disease monitoring, the authors also 
observed that liver resection itself could cause hepatocyte 
release into the bloodstream that subsequently disappeared 
after 2 weeks in case of not cancerous cells [128]. 
Using a green fluorescent protein (GFP)-transfected 
HCC orthotopic mouse model, Fan et al. were able to 
continuously monitor CTC-dynamics by in vivo flow 
cytometry and confirmed that circulating HCC cells 
correlated with tumor size and metastasis. Although they 
demonstrated that liver resection might decrease CTCs at 
an undetectable level, a progressive CTC-enhancement 
could be detected when tumors were not completely 
removed [134], supporting the idea that CTCs may be 
a useful tool to monitor residual disease or presence of 
metastatic lesions. 
Through a similar GFP-labeled HCC in vivo model, 
Yan et al. recently observed that, in response to Sorafenib 
treatment, a significant decrease in CTC-numbers and lung 
metastasis in addition to an increase in tumor necrosis and 
apoptosis as well as inhibition of tumor proliferation and 
angiogenesis [112]. 
Since CTC-presence in circulation may indicate 
tumor metastasis development, it might represent a helpful 
tool to guide treatments during neoadjuvant therapies 
before or after surgery. Importantly, not all HCC patients 
equally respond to Sorafenib. In this respect one of the 
reason might be found in the simultaneously inactivation 
of Ras/Raf/extracellular signal-regulated kinase (ERK) 
pathway and the activation of the phosphoinositide3-
kinase (PI3K)/protein kinase B (Akt) / mammalian 
target of rapamycin (mTOR) in tumor cells as well as 
CTCs. Very recently, Li et al. evaluated the activation 
(phosphorylation) of ERK and Akt in CTCs obtained 
from 109 HCC patients. After two weeks of Sorafenib 
treatment, all patients showed a decline in CTC-number, 
but the highest decrease occurred in those with high 
proportion of pERK+/pAkt- CTCs, suggesting it as the 
most treatment-sensitive phenotype. In particular, in 
patient with < 40% proportion of pERK+/Akt- CTCs, 
Sorafenib-response correlated with a longer progression 
free survival and a better clinical outcome compared to 
patients with < 40% [113]. 
Additionally, Sun et al. detected EpCAM+ CTCs in 
66.67% HCC patients and those with CTCs ≥ 2 per 7.5 
mL (approximately 41%) showed higher tumor recurrence 
rate than patients with CTCs < 2 per 7.5 mL (70.6% versus 
20.8%). Furthermore, EpCAM+ CTCs ≥ 2 were strongly 
associated with a shorter time of recurrence, greater 
vascular invasion, poor tumor differentiation and higher 
levels of alpha fetoprotein (AFP), an important HCC 
marker. Therefore the authors reported that determination 
of preoperative EpCAM+ CTC amount could be used as 
promising recurrence indicator [109]. 
In a pilot study Kelley et al. not only preceded to 
EpCAM+ CTCs detection and enumeration in 20 HCC 
patients, but more importantly they provided a CTC-
characterization by next-generation sequencing. The 
authors identified about 58 somatic non-synonymous 
mutations in all CTC-samples, among which there were 
some liver emblematic mutations (e.g. TP53, CTNNB1, 
PTEN, CDKN2A), non-liver mutations (e.g. ATM, BRAF, 
34 PLC na Flow cytometry  CD45- CD90+ 0-1.2 % In vivo tumorigenic assay na [54]
13 CellSearch System Positive immuno-magnetic selection 
DAPI+ CD45- CK+ 
EpCAM+ 
2.25 ± 1.54 
/ 7.5mL na na [132]
88 CellSearch System Positive immuno-magnetic selection 
DAPI+ CD45- CK+ 
EpCAM+ na na
Tumor size, TNM 
stage,
multi-nodularity, 
lymphatic invasion, 
mestasis, OS
[133]
Summary of CTC-studies conducted in PLC patients. Number of patients enrolled, platforms and methods used 
for CTC isolation and characterization, phenotype and number of isolated CTCs and correlation with clinical and 
pathological parameters or outcome of patient are reported, together with the relative references.
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KIT, members of ERBB and FGFR family) and completely 
novel variants (e.g. NOTCH, CSF1R, KRAS, SMAD4). 
Moreover, the presence of at least 1 CTC per 7.5mL of 
blood correlated with ≥ 400ng/mL and vascular invasion, 
confirming again the potential role of CTCs as biomarkers 
for HCC progression and invasion [131]. 
The statistically significant correlation of EpCAM+ 
CTCs with AFP ≥ 400ng/mL and vascular invasion was 
already been demonstrated in 2003 by Schulze et al. who, 
analyzing a total of 59 HCC patients and 19 controls, 
detected ≥ 1 per 7.5 mL in 30.5% of HCC group. The 
median overall survival was significantly shorter in CTC-
positive patients (460 days versus 764 days) and a higher 
frequency of CTCs was detected in patients with an 
advanced HCC stage (defined by Barcelona Clinic Liver 
Cancer (BCLC) staging system; BCLC C) compared to 
those with local limited disease [108].
Additionally, Guo et al. proved that patients 
underwent tumor resection with persistent preoperative 
and postoperative presence of EpCAM mRNA+ exhibited 
shorter time to recurrence and higher recurrence rate. 
Moreover, the authors showed that EpCAM+ CTCs 
enriched by negative selection (CD45-) could have been 
used as alternative tool to monitor treatment-efficiency 
instead of standard radiologic follow-up, with the benefits 
of better safety avoiding the side effects associated with 
X-rays exposure [115].
Although, majority of these studies were based 
on EpCAM+ CTC-selection, Li et al. highlighted the 
significant combination with the expression of EMT-
markers. Indeed, the authors were able to detect the 
presence of Twist (89.8%) or Vimentin (80.4%) positive 
CTCs in HCC patients. On the other hand, the co-
expression of both markers was present in 69.6% of 
CTC-positive patients and was significantly associated 
with portal vein thrombus, TNM staging and tumor size, 
suggesting that identification of Vimentin/Twist+ CTCs in 
addition to EpCAM+ CTCs could provide a better tool in 
the valuation of HCC mestastasis and prognosis. Hence, 
in order to avoid CTC-underestimation, it is essential to 
optimize CTC-detection methods, by possibly including 
EMT-markers. The authors also highlighted the correlation 
between CTC-levels and HCC prognosis after liver 
tumor’s resection or hepatic artery chemoembolization 
[135]. Unlike several studies in the context of liver 
resection, relationship between CTC-presence and HCC 
recurrence after liver transplantation (LT), has not been 
extensively described yet [136, 137]. Indeed further 
investigations of CTCs in LT clinical setting would 
certainly provide valuable information for prediction HCC 
prognosis after transplantation. 
Evidence of CTCs in cholangiocarcinoma
Dissimilar to hepatocarcinoma, very few CTC-
studies have been performed in CCA underlining that 
development of his promising field is required. 
First evidence dates back to 2008 when Yang et al. 
proved the existence of CD45- CD90+ CTCs in blood of 
patients with liver cancer, including CCA. Remarkably, 
this CTC-subset displayed tumor stem-like features, 
as evidenced by the expression of key stem-like genes 
including Bmi1, CD44, Oct4, Notch1, Wnt3a, Stat3, and 
HIF-1α [53, 54]. 
Later, Al Ustwani et al. tried to set a cut-off for 
positive CTC-value (2 CTCs/7.5 mL) in CCA with the use 
of CellSearch system and they identified presence of CTCs 
in 23% of CCA patients with a strong association with 
disease-stage. Moreover, at 12 months of follow-up, 25% 
of patients with positive CTC-value and 50% of those with 
negative CTC-rate were alive. Although no statistically 
significant correlation was found, a good trend between 
CTC-value and clinical outcome could be certainly 
observed. The inability to detect CTCs in a higher 
percentage of patients may found a possible explanation 
in the activation of EMT-program characterized by the 
loss of expression of epithelial antigens, such as EpCAM. 
Additionally, the limited number of patients enrolled 
in this study suggests that further deep investigation is 
required [132]. 
In a very latest work, the group of Yang et al. 
proceeded to CTC-enumeration in 88 CCA patients, 
among which 17% resulted positive for ≥ 2 and 9% for 
≥5. Larger CTC-number appeared to correlate with a 
more extensive tumor burden, represented by larger 
tumor size, multi-nodularity, lymph node invasion and 
distant extrahepatic metastasis. Notably, a CTC-number³ 
≥ 5 correlated with a shorter survival in intrahepatic 
CCA patients showing a trend toward its association with 
survival in non-metastatic CCA patients. Although this 
represents a pioneer study in CCA field, unfortunately 
several limitations are evident. First, CTC-detection 
relies on EpCAM expression that may be responsible of 
a possible CTC-underestimation. In addition, the entire 
study trusts on a very heterogeneous group of CCA 
patients in terms of CCA classification, presence/absence 
of metastasis and type of treatment, without focusing on 
specific CCA-subtypes (e.g. intrahepatic CCA, distal CCA 
and perihilar CCA or metastatic and non-metastatic CCA). 
Furthermore, since primary sclerosing cholangitis (PSC) 
represents a well-known risk factor for CCA-initiation, the 
study also included several PSC-associated CCA patients. 
Although, no detectable levels of CTCs were found, 
sample size was too small to stem solid conclusions [133, 
138]. 
Hence, despite data on prognostic role of CTCs in 
CCA are very scarce, these studies suggest the importance 
of CTCs as a valuable tool in CCA clinical management. 
In conclusion, similarly to other tumor models, the 
large amount of PLC-CTC studies allow the definition of 
key findings such as correlation with patients’ clinical and 
pathological data (tumor grade, TNM stage, recurrence, 
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etc.) and treatment response, CTC-prognostic significance, 
CTC-heterogeneity as well as the inadequacy of EpCAM 
as only marker CTC-isolation and necessity to improve 
CTC-detection methods [53, 54, 108, 109, 112, 113, 115, 
128, 131-138]. However, current PLC CTC-field requires 
to be further investigated.
PHENOTYPICALLY DIVERSE CTC-
SUBTYPES: STEM-LIKE PLASTICITY 
TRIGGERS A CONTINUUM OF EMT AND 
MET STATES
It’s important to underline that not all CTCs are 
able to invade blood circulation [139] and only a small 
subset is capable to initiate secondary tumors [96, 99]. 
Mirroring complex heterogeneity of primary tumor 
cells, phenotypically distinct CTC-subtypes (including 
epithelial, hybrid epithelial-mesenchymal, mesenchymal 
and stem-like) expressing a variety of surface proteins 
with different behaviors (proliferation, cell cycle arrest, 
epithelial differentiation, dissemination) can co-exist in the 
circulation. These subpopulations are not strictly distinct 
as there is a continuum between their different stages [45, 
104, 140, 141].
Indeed, epithelial CTCs maintain the expression of 
epithelial-specific markers, such as EpCAM and different 
type of cytokeratins such as CK8, CK18, CK19 thus 
retaining their original phenotype [106, 108, 109, 113, 
131-133]. On the other hand, accumulating evidence 
shows that, as result of a complete EMT-adaptation of 
primary cancer cells, CTC-subsets retain a mesenchymal-
like phenotype, characterized by an up-regulation of 
Vimentin and Ncadherin genes [45, 135, 142]. Because 
of EMT-process, tumor cells and derived-CTCs can 
undergo to various alterations during the early stages of 
carcinogenesis, leading to cancer cell dissemination and 
micrometastasis establishment. Indeed, mesenchymal 
phenotype of CTCs promotes migration and invasion, as 
well as the escape from immune surveillance, resistance 
to anoikis and shearing forces in the bloodstream [45, 
101, 104, 135]. In this respect, EMT-positive CTCs 
could be considered as potential indicators of aggressive 
relapse and more importantly an essential tool for a better 
understanding of tumor recurrence. 
In contrast, it has also been suggested that different 
CTC-subsets may be in transition from epithelial to 
mesenchymal state, retaining several intermediate 
phenotypes [101, 102, 104], as reported in patients 
with metastatic non-small-cell lung cancer (NSCLC) 
[143], early and metastatic breast cancer [144, 145] and 
prostate cancer [145]. Nel et al. in their study detected 
both epithelial (panCK+ and/or EpCAM+ cells) and 
mesenchymal (Vimentin+ or Ncadherin+ cells) CTCs in 
almost all enrolled HCC patients. Additionally only 36% 
of patients retained both epithelial and mesenchymal 
CTCs, underlining the concept that a variety of CTC-
populations with different proportions and diverse roles 
could be identifiable in peripheral blood of tumor patients 
[146]. 
Instead of single cells, further complexity is 
described by the presence of CTCs as cluster (CTC-
clusters) including relatively small entities (the majority) 
or dozens (the minority). At this regard, hybrid-EMT 
cells, preserving both epithelial (cell-cell adhesion) and 
mesenchymal (migration) features, are the ones who 
mostly undergo to a “co-migration” as CTC-clusters [98]. 
Interestingly, maintenance of a hypoxic microenvironment 
within CTC-cluster is essential to activate EMT-process 
thus rendering them much more resistant to apoptosis and 
tumorigenic as compared to single CTCs [142]. Therefore, 
size of CTC-clusters is indeed a critical issue. Overall, 
continuous presence of CTC-clusters in blood correlated 
with different levels of malignancy and metastatic potential 
as described in breast and prostate cancer patients with 
a dramatic shorter progression-free and overall survival, 
respectively [147]. In a recent work, Aceto et al. proved 
that CTC-clusters not represent an aggregation or a clonal 
progeny of individual CTCs into the vasculature, but more 
likely oligoclonal clumps of tumor cells within primary 
tumor mass. Although CTC-clusters represented only 
2-5% of CTC-events in the circulation (likely due to their 
faster clearance rate as result of their entrapment in small 
capillaries), they possessed higher metastatic potential 
(about 23-50 times) than single CTCs. RNA sequencing 
of purified CTC-clusters permitted the identification of an 
important cell-junction component, plakoglobin, as a key 
orchestrator of CTC-cluster formation and stabilization, 
thus representing a potential target to reduce metastatic 
spread of breast cancer [147]. 
Only one small study reported the presence of CTC-
clusters in HCC patients in which the authors detected 
mesenchymal phenotype of CTC-cluster in a liver cancer 
patient at T3N1M1 clinical stage [148]. With the exception 
of this analysis, presence of PLC-associated CTC-clusters 
has not been deeply evaluated yet.
Among the wide CTC-spectrum, the identification 
of stem-like “metastasis-initiating” CTC-subset may 
provide an attractive approach for both systemic cancer 
diagnosis and therapy. In view of tumor plasticity, the 
aforementioned EMT-program couples the two key 
concepts of metastatic-CTCs with relapse-initiating 
CSCs. In this regard, emerging evidences suggest that 
only a specific subset of CTCs with stem-like properties 
represents the ‘lethal seeds’ with superior adaptation 
under harshly adverse conditions of bloodstream as well 
as metastatic stroma where re-initiate growth and form 
metastases [96, 97, 99, 102-105]. Accordingly, with 
CSC-hypothesis, self-renewal ability and resistance to 
anti-cancer drugs make stem-like CTCs particularly 
hard to eradicate, leading to the permanence of minimal 
residual disease in cancer patients with a consequent 
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cancer recurrence [140]. In this respect, analysis of stem-
like CTCs is of fundamental relevance to provide unique 
molecular information about minimal residual disease in 
patients without clinically detectable metastatic lesions 
as well as to prevent tumor distant metastasis [110, 111]. 
In some cases, stem-like CTCs express both classical 
stem-like markers (e.g.CD44 [40, 44, 53, 54, 149-151], 
ABCG2 [109], ALDH1 [40, 44, 150, 151], DCLK1/
Lgr5 [150], CD90 [54] and CD133 [109, 145]) as well 
as EMT-markers (e.g. Vimentin [109, 152], Twist [135]) 
reinforcing the concept that an aberrant activation of 
EMT-program enhances stemness properties and tumor-
initiation potential of CTCs. Emerging evidence suggest 
that CTCs with hybrid or partial EMT-state, rather than 
those with a ‘fully’ epithelial or mesenchymal phenotype, 
retain stem-like features and are capable of completing 
the invasion-metastatic cascade. The presence of this 
great level of heterogeneity makes very challenging to 
find an accurate method for CTC-detection in blood 
patients. In order to target the diverse degree of EMT in 
the entire CTC-population, a combination of epithelial, 
mesenchymal and stem-related markers likely represent 
the ‘gold standard’ for CTC-enrichment [98]. A summary 
of different layers of CTC-heterogeneity is shown in 
Figure2 and Figure3.
STEM-LIKE CTCs IN LIVER CANCER
One of the key problems in liver cancer treatment 
is the high recurrence rate, most probable due to presence 
of undetectable micrometastasis at initial stage [108]. 
Although multiple studies have demonstrated the existence 
of stem-like CTCs in HCC, a precise characterization 
of this highly aggressive population as well as the 
contribution of CSC to PLC -metastatic outgrowth need 
to be elucidated yet. 
Based on finding in HCC tumor specimens, Yang 
et al. used CD90, a well-described liver CSC-related 
marker to characterize stem-like CTCs by investigation of 
CD45- CD90+ cells in blood samples of PLC patients. The 
authors identified CD45- CD90+ CTCs in 91% of samples 
and demonstrated that this cell population expressed key 
stem-like genes including Bmi1, CD44, Oct4, Notch1, 
Wnt3a, Stat3, and HIF-1a compared to CD90+ tumor-
tissue cells. Moreover, CD45- CD90+ CTCs were more 
tumorigenic compared to CD45- CD90- population when 
Figure 2: Blood Dissemination of Different CTC-subtypes. Primary tumors, heterogeneously composed by bulk tumor cells and 
CSCs, can shed several CTCs, but only a minim percentage can survive in the bloodstream and only a minority is able to initiate metastatic 
tumor growth in a diverse organ. CTCs meet three main obstacles to their survival and dissemination: shear forces and collisions with 
leukocytes generated by blood flow, defense activity of immune system, absence of cell-matrix interactions that triggers an apoptotic 
process called anoikis. Mirroring complex heterogeneity of primary tumor cells, phenotypically distinct CTC-subtypes can co-exist in 
the circulation: epithelial, intermediate epithelial-mesenchymal, fully mesenchymal and stem-like CTCs. Moreover, CTCs with hybrid 
epithelial-mesenchymal phenotype can collectively migrate as CTC-clusters, instead of single cells. Emerging evidences suggest that only 
the subset of stem-like CTCs is endowed with ‘metastasis-initiating’ capability. 
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orthotopically injected in the liver of severe-combined 
immunodeficient mice. Notably, a positive correlation 
between the number of CD45- CD90+ CTCs and tumor 
size was proved, whereas no association with disease free 
or overall survival was determined, probably due to the 
limited number of cases and short follow-up period. In 
addition, because of detectable levels of CD90+ CTCs 
in patients with small tumors (<5 cm) and dysplastic 
nodules, a fundamental role of this subset in early stage 
of hepatocarcinogenesis was revealed. All these findings 
suggested a potential implication of circulating stem-like 
HCC cells in disease surveillance [53, 54]. 
In a subsequent study, same authors detected 
CD45- CD90+ CD44+ CTCs in 68.3% of enrolled HCC 
patients, demonstrating a significant correlation with 
tumor size, TNM stage and, more relevantly, with post-
hepatectomy recurrence and survival. Indeed, in presence 
of recurrence, average levels of CD45- CD90+ CD44+ 
CTCs were 0.02% as compared to 0.01% of non-recurrent 
patients. Moreover, the median recurrence-free survival 
(6 months) as well as overall survival (30 months) were 
lower compared to 46.5 months and 57.1 months of 
non-recurrent patients, respectively. Therefore, stem-
like CTCs > 0.1% emerged to have a strong prediction 
ability of recurrence and survival, also much higher than 
conventional parameters, such as TNM staging, tumor 
size, vascular invasion [149]. 
Recently, Zhu et al. relying on the fact that stromal 
cell-derived factor-1 (SDF-1)/CXCR4 axis has a key 
function in regulation of cell migration and homing, 
hypothesized that CD90+ CXCR4+ cells could represent 
putative stem-like CTCs. Indeed, in only CD90+ CXCR4+ 
transplanted mice it was possible to detect tumor cells in 
circulation and tumor metastasis in distant organs thus 
suggesting that CD90+ CXCR4+ CTCs potentially retain 
stem-like metastasis initiating capability [139]. 
Although, all these studies suggested CD90 as 
a potential marker for circulating-CSC identification, 
several limitations such as its abundant expression also in 
normal hepatic stem/progenitors cells, in mesenchymal-
like cells (e.g. fibroblasts) and vascular cells are present, 
thus indicating a lack of specificity [153]. 
Furthermore, Sun et al. suggested EpCAM as a 
reliable marker for stem-like CTCs, considering that it is 
typically co-expressed with other CSC-related markers, 
such as CD133 and ABCG2, or associated with β-catenin 
accumulation and Wnt pathway activation. Moreover, 
in some cases, patient derived EpCAM+ cells exhibited 
a mesenchymal phenotype (Vimentin+/Ecadherin-) and 
higher tumorigenic potential when injected in mice rather 
than the EpCAM- cells. The authors also provided an 
analysis of EpCAM+ CTC-count before and after curative 
surgery, subdividing patients according to alterations 
between preoperative and postoperative EpCAM+ CTC-
levels using a cut off of 2 CTCs per 7.5 mL of blood. They 
demonstrated that patients with persistent preoperative and 
postoperative CTC count ≥ 2 were characterized by higher 
recurrence rate and shorter time to recurrence, underlining 
Figure 3: A Continuum Between Different CTC-Subtypes. Among CTC-subpopulations, there are several phenotypes: epithelial 
CTCs that maintain the expression of original epithelial-specific markers (e.g. EpCAM and cytokeratins (CKs)); hybrid CTCs represented 
by cells in transition from epithelial to mesenchymal state, as demonstrating by the concomitant expression of both epithelial and 
mesenchymal markers; stem-like CTCs expressing both classical stem-like markers (such as CD90 and CD44) and mesenchymal-like 
markers (Vimentin and Twist); mesenchymal CTCs which show an upregulation of mesenchymal-like markers (such as Vimentin and 
Ncadherin). These subpopulations are not strictly distinct but a continuum between their different stages is probably existent.
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the prognostic significance of HCC CTC-positivity [109]. 
A limitation of this study is represented by the exclusive 
use of EpCAM marker for stem-like CTC-isolation. 
Indeed, considering the fact that CSC-features are often 
associated with EMT-traits with a consequent down-
regulation of EpCAM expression, this only marker is not 
sufficient to identify liver stem-like CTCs.
For this reason, Cheng et al. proposed Lin28B, 
an oncofetal microRNA-binding protein with a role 
in regulating the expression of important pluripotent 
factors such as Oct4, Nanog and Sox2. Thus, the authors 
proceeded to the detection of Lin28B transcript by RT-
PCR and found its expression in 33.3% of HCC cases, 
with a significant association with larger tumor size, higher 
tumor grade and earlier recurrence after hepatectomy. 
However, Lin28B mRNA was also detected in 5% of 
controls, thus indicating that further studies are surely 
needed to clarify its prognostic value. These findings 
importantly supported the redefinition of HCC staging 
system from TNM to TNMC (C for CTCs), accentuating 
the potential predicting value of CTCs [154]. 
On the other hand, relying on the expression of 
intercellular adhesion molecule 1 (ICAM1), Liu et al. in 
2013 detected CD45- ICAM1+ cells in 60 patients with a 
frequency higher than 0.157% and a correlation with more 
aggressive tumor behavior and worse patients’ outcome. 
Moreover, CD45- ICAM1+ cells possessed in vitro stem-
like properties, as demonstrated by sphere formation 
and in vivo tumor induction. Notably, ICAM1 inhibition 
by shRNA resulted in reduced tumor development and 
metastasis in mice, thus suggesting ICAM1 a good 
therapeutic target [155]. 
Strengthening the link between EMT-process and 
CTCs, a new mechanism for stem-like CTC-generation has 
been recently proposed. Indeed, it has been hypothesized 
that hepatic transmembrane 4 L six family member 5 
(TM4SF5), which is overexpressed in HCC and implicated 
in EMT-program, may have a potential role in generating 
stem-like circulating HCC cells through the interaction 
with CD44 protein. After the binding of TM4SF5 to 
CD44, an activation of c-Src/STAT3/Twist1/Bmi1 
signaling pathway promoted the release of metastatic 
stem-like CTCs in the blood of orthotopic mouse model. 
Interestingly, the knockdown of either TM4SF5 or CD44 
or the disruption of their interaction abolished the presence 
of CTCs and metastatic properties [156]. 
Among all the studies presented here, the authors 
used different surface markers to define and detect stem-
like CTCs in the blood of HCC patients, and in all cases, 
the identified subpopulations possess putative stem-
like features. This may be attributable to the significant 
heterogeneity of CTCs, as already mentioned before. 
Since only a minority of stem-like cells represent the 
driving force of tumor progression and metastasization, 
we can assert that the presence of CTCs itself is necessary 
but not sufficient for the initiation of metastasis. Hence, 
identifying the stem-like CTC-subset would provide 
more relevant prognostic information rather than total 
CTC-counts. At this regard, few studies emphasized the 
prognostic potential of stem-like CTC-levels in patients 
underwent curative resection, underlining the correlation 
between persistent pre- and post-operative presence of 
metastasis-initiating CTC-subset together with lower 
relapse-free survival [109, 157]. 
CONCLUSIONS AND FUTURE 
DIRECTIONS
There is general consensus in cancer research 
field regarding intriguing biological features and clinical 
significances of stem-like cells within single tumors. Due 
to its key role in tumor recurrence and metastasis spread, 
they represent a therapeutic challenge subpopulation. 
Thus, supposing that CSCs account for tumor metastasis, 
stemness features should be found among tumor cells 
disseminated from primary tumors including CTCs. 
Although it has been shown that activation of EMT-
program, by generating a subpopulation endowed 
with stem-like traits capable of self-renewal and drug-
resistance, represents a central biological link between 
CSCs and CTCs, many ambiguities do exist and a solid 
molecular signature which confirmed their correlation still 
need to be established. 
Indeed, central debate aims to understand whether 
tumor cells undergoing EMT-process result in a more 
mesenchymal or even more stem cell-like phenotype 
and what fraction of CTCs has better metastatic seeding 
potential or increased therapeutic resistance. 
Moreover, similar to normal stem cells and because 
of dynamic state of CSCs, a continuum of phenotypically 
distinct CTC-subtypes ranging from epithelial, hybrid 
epithelia-mesenchymal, mesenchymal and stem-like may 
co-exist in the circulation, reinforcing the concept of 
tumor heterogeneity (Figure2, 3). 
It is important to note that, CTC-detection 
remains technically challenging due to very low CTC-
concentrations (one tumor cell against millions of blood 
cells). Thus, their identification and characterization 
require extremely sensitive and specific methods, which 
are usually represented by a combination of multiple 
procedures. Moreover, current PLC-CTC detection 
methods use the epithelial marker EpCAM, which may 
underestimate CTC-numbers and potentially fail to detect 
a critical subpopulation. If only CTCs that undergo EMT 
are those with stem-like features, then a combination 
of epithelial, mesenchymal and stem-related markers 
should be included. Because not all detected CTCs have 
metastatic and relapsing potential, a simple enumeration 
of CTCs without molecular characterization may lead to 
wrongful clinical conclusions. Elucidating CTC-biology at 
molecular level based on genomic profile would improve 
detection and isolation of the potentially disseminating 
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CTC-subsets. In this regard, single-cell transcriptomic 
analyses of individual PLC-CTCs would benefit to guide 
clinical treatments and achieve much improved cure rate 
in liver cancer patients.
Exploring the existence of disseminating stem-
like CTCs and their unique ability to initiate relapse 
and propagate metastatic growth, is essential to move to 
effective personalized therapy with the overall objective of 
identifying prognostic and diagnostic markers as well as 
novel therapeutic targets. Therefore, it would be pivotal to 
rule out a possible recurrence and metastatic dissemination 
at the time of diagnosis, by investigation of stem-like 
metastasis-initiating CTCs in order to discriminate high-
risk factors of PLC recurrent patients after curative 
resection as well as to identify new therapeutic agents by 
targeting liver stem-like circulating cancer cells.
BOX 1
Conventional approaches for CTC-enrichment
Since approximately less than 1 CTC is present in 
107 blood cells, they represent a very challenging subset 
to detect [110, 111].
In recent years, many different CTC-isolation 
technologies have emerged to improve CTC-enrichment 
rates from other blood components [109, 165-171]. Based 
on diverse CTC-features, most approaches relied on 1) 
physical properties, 2) presence of specific cell markers 
and 3) combination of both. A summary of diverse 
methodologies is shown in Figure1.
Methods based on physical properties
Strategies for CTC-enrichment centered on 
biophysical properties have gained increasing popularity 
and rely on the ability to discriminate between CTCs 
and other cells (e.g. leukocytes) based on physical 
characteristics such as size, density and electric charge 
[172] (Figure1).
Several studies of CTC-physical properties revealed 
that these heterogeneous cells are typically larger (12-25 
μm) than other white blood cells (8-14 μm) [173-177]. 
Two commercial size-based filtration platforms, ISET 
(Rarecells Diagnostics) and ScreenCell (ScreenCell), 
have been used to enrich CTCs based on their larger 
morphology compared to leukocytes. For instance, ISET, 
or ‘isolation by size of epithelial tumor cells’ was used 
to enrich fixed CTCs from blood samples through 8-mm 
pores polycarbonate [178].
Density gradient centrifugation is a conventional 
approach for separating blood components because of 
differences in their sedimentation coefficients. Indeed 
CTCs have a specific gravity (1.056) compared to red 
blood cells (1.092) and leukocytes (1.065). Although 
not originally developed for CTC-isolation, researchers 
have used Ficoll-Paque in this application and depending 
on their density, cells distribute along the gradient after 
centrifugation and erythrocytes or polymorphonuclear 
leukocytes migrate to the bottom, whereas mononuclear 
leukocytes and CTCs remain at the top [175, 179]. In 
addition to density gradient separation, OncoQuick system 
(Greiner Bio-one) incorporates a porous membrane above 
the separation media, which captures CTCs while allowing 
contaminating blood cells with similar densities to CTCs 
[175].
Dielectrophoresis (DEP) based method, relies on 
diverse electrical properties of tumor cells, which depend 
on composition (e.g. cell membrane, nucleus, organelles), 
morphology (e.g. size, shape), and phenotype [180, 181]. 
During DEP isolation, an attractive or repulsive force is 
exerted on a cell causing it to move towards or away from 
the electrical field source. The commercial technology 
DEPArray (Silicon Biosystems) traps single cells in DEP 
cages generated via an array of individually controllable 
electrodes [182-187].
These approaches allow viable CTC-isolation 
from blood avoiding the use of tumor markers. On the 
other side, cancer patient blood may contain a mixture 
of diverse cells deriving from organs which are not 
necessary tumor cells. Moreover, CTCs may retain larger 
size than leukocytes making them not suitable for ISET or 
ScreenCell filters. Even if tumor cells are captured on the 
membrane, it may be difficult to detach them for further 
molecular examination. Density gradient centrifugation 
may instead lead to a loss of tumor cells resulting in false-
negative results. 
Methods based on immunoaffinity
The second group mainly relies on the use of 
antibodies against tumor specific biomarkers (Figure1). 
Indeed, immunoaffinity-based approaches targeting 
EpCAM is the most used technique for positive selection 
of CTCs because its expression is virtually universal 
(albeit at variable levels) in cells of epithelial origin and 
absent in blood cells [109, 166]. 
Alternative CTC-isolation platforms deploy a 
strategy of negative selection (such as for CD45- cells) to 
remove mononuclear cells and primarily leukocytes [109, 
188].
Other isolation platforms have developed magnetic 
microbeads coated with antibodies against CTC cell-
surface proteins such as EpCAM. These include a 
magnet-activated cell sorting system (MACS, Miltenyi) 
and Dynabeads (Invitrogen) that provide a release buffer 
to remove the beads from cells [188, 189]. Recently, the 
AdnaTest platform (AdnaGen GmbH) combines several 
antibodies specific to unique cancer types, with reverse 
transcription-PCR and multiplex PCR to analyze CTC-
expression of tumor markers [190].
Nevertheless, the only clinically validated FDA-
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approved test to capture and enumerate CTCs is 
represented by Cell Search® system. In this platform, 
tumor cells are first immunomagnetically enriched by 
EpCAM antibody-coupled magnetic beads. Subsequently, 
EpCAM positively recovered cells are recognized for 
negative CD45 staining, positive DAPI nuclear content 
and cytoplasmic epithelial markers cytokeratin (CK) 8, 
CK18, CK19 [167]. 
This second group of methods provides alive 
epithelial cells, which may be used for further analyses 
as well as in vitro growth. However, although immune-
enrichment methods could acquire high CTC-purity, on 
the other hand they might miss the highly metastatic tumor 
cells which, due to the EMT-process, are characterized 
by decreased expression of epithelial markers and the 
acquisition of mesenchymal features [168]. Therefore, 
alternative enrichment approaches should also consider 
the combination with mesenchymal markers. Since 
EpCAM and CKs are also expressed by circulating 
epithelial non-tumor cells, thus they are not CTC-specific 
and can lead to false positives. Additionally, purity-related 
issues may arise due to non-specific binding of cells to the 
microbeads. These disadvantages are mostly problematic 
in the clinical setting. 
Combinatorial methods
Most recently, the microfluidic-based “CTC-
chip” has attracted intense attention due to its enhanced 
sensitivity and specificity in CTC-purification [169, 
170] (Figure1). This third group allows precise control 
of tiny volumes of fluids under flow through antibody-
coated microspots providing a functionalized surface and 
dynamic flows that exclude nonspecific binding [171]. 
Although such platforms have increased the sensitivity 
of CTC-detection and capture, their low flow rates don’t 
allow to process sufficient volume sample for a high CTC-
yield. 
Several microfluidic-based platforms have more 
recently incorporated a combination of size- and 
immunoaffinity-based approaches to develop integrated 
systems and improve CTC-recovery [147, 191-194]. 
Ozkumur et al. described the microfluidic CTC iChip, 
which combines hydrodynamic sorting, inertial focusing, 
and magnetic sorting of pre-labeled CTCs from blood 
[195]. An alternative microfluidic approach involves the 
use of microtraps which take advantage of CTC-size and 
deformability of [196].
Major challenges for these new techniques include 
cell fragility, blood tendency to clog, and high blood 
cellularity. Relevant parameters are sensitivity, purity 
(depending on leucocytes contamination rate), time for 
isolation, quality of cell morphology and cell structure for 
further morpho-immuno-molecular analyses, and viability 
for culture tests. 
KEY POINTS
• Poor prognosis and high recurrence represent 
leading causes of primary liver cancer mortality 
• Spread of circulating tumor cells (CTCs) in 
the blood accounts for tumor recurrence and 
metastasis initiation 
• CTCs can be considered an useful tool to 
monitor early blood dissemination of liver 
tumor cells and predict liver cancer progression, 
prognosis and therapy response
• CTCs are likely heterogeneous and only a 
subset of CTCs can survive in the bloodstream, 
migrate to distant sites and establish secondary 
tumors. Consistent with cancer stem cell (CSC) 
hypothesis, stem-like CTCs might represent 
a potential source for cancer relapse and 
metastasis
• Aberrant activation of a latent embryonic 
program (known as the epithelial-mesenchymal 
transition, EMT) generates undifferentiated 
cancer cells endow with stemness traits, 
thus providing a ready source of CSC-
state. Although it might represent a crucial 
biological link between CSCs and CTCs, many 
ambiguities do exist and a solid molecular 
signature that confirmed their correlation still 
need to be established 
• Similar to normal stem cells and as a 
consequence of dynamic state of CSCs, a 
continuum of phenotypically distinct CTC-
subtypes ranging from epithelial, partial-EMT, 
mesenchymal and stem-like may co-exist in the 
circulation, reinforcing the concept of tumor 
heterogeneity
• Identification of stem-like metastasis-initiating 
CTC-subset may provide valuable clinically 
prognostic information in the context of 
personalized care management
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